The last 24 hours offered an important lesson over just how closely analysts and investors are tracking every movement on the immunotherapy front in cancer R&D.
The big biotech worked a deal with Eisai, offering to cover half of the research and development costs of a pair of mid-stage Alzheimer's therapies and adding an unspecified package of milestones and an upfront in exchange for half the potential profits.
After the markets closed on Tuesday, Xoma put out the word that its main pipeline asset, gevokizumab (Xoma 052) flunked a Phase II program for erosive osteoarthritis of the hand, ending any shot it had at a broad pivotal study in that indication.
Watch out, Google. Genome pioneer Craig Venter, well known for elbowing his way to the front of a scientific race, is launching a new company that will tackle the multitude of diseases that affect aging.
AbbVie's promising oral hepatitis C combo treatment is rolling along toward FDA approval, and the drugmaker unveiled a deeper set of Phase III data in which the cocktail cured nearly 100% of patients in a tough-to-treat population.
Theravance, the biotech engine behind GlaxoSmithKline's bright future in COPD, is gearing up to split in two next quarter, with one publicly traded company handling its revenue-generating drugs and the other leading the charge on R&D.
Shares of Oxygen Biotherapeutics shot up 30% Tuesday morning after the Morrisville, NC-based biotech announced that the FDA had lifted a clinical hold on Oxycyte, an experimental drug the military has been supporting as a possible treatment for traumatic brain injury.
With his nearly 20-year stint at Roche coming to an end, longtime Roche Chairman Franz Humer said he's leaving the drugmaker just as it gets out from under Genentech-related debt, clearing the way for some dealmaking and an R&D jump-start.
With IPOs still booming, follow-on financings sizzling and venture capital rolling in at a steady pace, the biotech industry has been stocking up on billions of dollars in cash.
According to new research published online Monday at the Journal of Clinical Oncology, 63% of the patients taking the immunotherapy were alive after one year and 43% were still alive after two years on the drug. And the researchers say that the durable response was also reflected in patients who had stopped taking the drug.
Martin's tenure has seen the company build blockbuster revenue from its HIV franchise while creating a new standard of care in the hepatitis C arena.
With some of its larger rivals already at work on biotech knockoffs, Indian drugmaker Lupin is on the hunt for partners to help shepherd it into the biosimilar fray, taking aim at top-selling treatments soon to come off patent.
For several years now, scientists working on an HIV vaccine have been focused on a small set of patients whose immune systems were able to generate rare antibodies able to vanquish most strains of the lethal virus. And over the weekend a team of scientists from South Africa and the U.S. say that one woman--dubbed CAP256-VRC26--may have offered a key to do just that.
Roche is prepping for a human study to see if one of their GABA inhibitors can help boost the IQ of young people with Down syndrome, recruiting 180 patients, according to a report from Bloomberg. And a small biotech inspired by the work of Stanford University investigator Craig Garner is taking the same approach in the clinic with a drug dubbed BTD-001.
Galapagos NV's collaboration with GlaxoSmithKline has hit a roadblock. Late last week the Belgian biotech reported that its Big Pharma partner had hit the brakes on a Phase II study of GSK2586184 for lupus after a first look at the data failed to demonstrate a positive effect.
More than two years ago Roche CEO Severin Schwan picked the cancer drug MetMAb out of the pipeline as one of the company's top blockbuster prospects. But on Monday its oncology R&D arm at Genentech was forced to halt a Phase III combo study matching MetMAb with Tarceva in a failed effort to block metastasis in non-small cell lung cancer after an independent monitoring group flagged the attempt for futility.
The FDA has granted its fast-track status to Actelion's Phase III drug for C. difficile-related diarrhea, promising a shorter path to approval for the antibiotic treatment.
Durham, NC's Scynexis is queuing up for a $55 million IPO, looking to ride the wave of biotech bullishness and raise cash for its in-development anti-infective.
Celgene's roving band of dealmakers has selected San Diego-based Abide Therapeutics for its latest option package, taking an equity stake in the biotech as it settles into a front row seat on its progress regarding a broad R&D front and gaining first dibs on Abide's lead program.
A rejuvenated R&D shop has given Bayer a spate of potential blockbusters, and CEO Marijn Dekkers wants to see more where that came from. The German drugmaker is planning to substantially increase its research budget over the next three years and set aside a boatload of cash for M&A.